AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21291441 — intervention group
Group type: EXPERIMENTAL
Intervention: ParentCorps (13 group sessions for parents and children facilitated by teachers and mental health professionals)
Number of subjects: 171
Study 21291441 — intervention group
Group type: EXPERIMENTAL
Intervention: ParentCorps
Number of subjects: 171
Study 19850347 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 764
Study 17094038 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal treatment with intravenous gammaglobulin (IVIG) and/or corticosteroids
Number of subjects: 71
Study 15277417 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 33
Study 15277417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11298254 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication information leaflets in addition to verbal information
Number of subjects: 54
Study 11298254 — intervention group
Group type: COMPARATOR
Intervention: Verbal medication information by nurse or psychiatrist (Control)
Number of subjects: 54
Study 9404207 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7937786 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of the advanced glycation inhibitor aminoguanidine to diabetic patients
Number of subjects: 0
Study 7937786 — intervention group
Group type: COMPARATOR
Intervention: AGE-modified LDL
Number of subjects: 0
Study 7937786 — intervention group
Group type: COMPARATOR
Intervention: Native LDL incubated with synthetic AGE-peptides
Number of subjects: 0
Study 2908716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin 50 mg twice daily
Number of subjects: 12
Study 2908716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin 100 mg twice daily
Number of subjects: 12
Study 2908716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin 200 mg twice daily
Number of subjects: 12
Study 2908716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31519517 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram + Memantine (ESC/MEM)
Number of subjects: 95
Study 31519517 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram + Placebo (ESC/PBO)
Number of subjects: 95
Study 29285613 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk adapted damage control orthopedics
Number of subjects: 0
Study 29285613 — intervention group
Group type: COMPARATOR
Intervention: Standard orthopedic treatment (implied control)
Number of subjects: 0
Study 28109313 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Healthcare Choices podcast
Number of subjects: 0
Study 28109313 — intervention group
Group type: COMPARATOR
Intervention: Typical public service announcements about health issues
Number of subjects: 0
Study 25686680 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 147
Study 25686680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 25686680 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147
Study 23639861 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowman Birk Inhibitor (BBI) complex
Number of subjects: 0
Study 23639861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21624036 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU) treatment during pregnancy
Number of subjects: 2830
Study 21624036 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole/carbimazole (MMI) treatment during pregnancy
Number of subjects: 2830
Study 21624036 — intervention group
Group type: COMPARATOR
Intervention: No antithyroid treatment during pregnancy
Number of subjects: 2830
Study 18573692 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care (HC)
Number of subjects: 31
Study 18573692 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 31
Study 16584345 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft (BG)
Number of subjects: 27
Study 16584345 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 27
Study 16584345 — intervention group
Group type: COMPARATOR
Intervention: Bone graft plus a bioabsorbable collagen membrane (BG + C)
Number of subjects: 27
Study 15043176 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videotape (20-minute)
Number of subjects: 160
Study 15043176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no videotape)
Number of subjects: 160
Study 10767063 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D spiral sequence
Number of subjects: 15
Study 10767063 — intervention group
Group type: COMPARATOR
Intervention: 2D spiral sequence
Number of subjects: 15
Study 8807647 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized rigid contact lens fitting protocol
Number of subjects: 30
Study 1402218 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (200 mg t.t.d.)
Number of subjects: 46
Study 1402218 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (200 mg t.t.d.)
Number of subjects: 46
Study 1402218 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (100 mg t.t.d.)
Number of subjects: 46
Study 1402218 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 6359885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 40
Study 6359885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31234665 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated schedule with three injections at weekly intervals
Number of subjects: 47
Study 31234665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster schedule with two administrations in 1 day
Number of subjects: 47
Study 29540213 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) including algorithm-driven antihypertensive treatment using single-pill combination (SPC), motivational conversation, telephone-based follow-ups, and discounts on SPC antihypertensive medications.
Number of subjects: 1000
Study 29540213 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) provided in four polyclinics.
Number of subjects: 1000
Study 29540213 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI)
Number of subjects: 1000
Study 29540213 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1000
Study 27107025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) using Japanese cedar (JC) pollen extract
Number of subjects: 40
Study 27107025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24867693 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (INT), thrice weekly sessions of four exercises, 3‐4 sets/exercise of 10‐15 repetitions at 12‐15 repetition maximum load
Number of subjects: 30
Study 24867693 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 30
Study 24867693 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy age‐matched subjects (REF)
Number of subjects: 30
Study 19586136 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 36
Study 19586136 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 36
Study 19586136 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 36
Study 16390397 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) chemoprophylaxis, daily for 1 year
Number of subjects: 109
Study 16390397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no INH)
Number of subjects: 109
Study 16390397 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) chemoprophylaxis
Number of subjects: 109
Study 11173138 — intervention group
Group type: EXPERIMENTAL
Intervention: bcl-2 positive patients
Number of subjects: 400
Study 11173138 — intervention group
Group type: COMPARATOR
Intervention: bcl-2 negative patients
Number of subjects: 400
Study 9705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI >= 30 kg/m2)
Number of subjects: 2836
Study 9705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2836
Study 9705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (HT)
Number of subjects: 2836
Study 9705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemia (HC)
Number of subjects: 2836
Study 9705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridaemia (HTG)
Number of subjects: 2836
Study 9705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated LDL
Number of subjects: 2836
Study 9705020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL
Number of subjects: 2836
Study 7805428 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin twice daily for 9 days
Number of subjects: 76
Study 7805428 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin twice daily for 9 days
Number of subjects: 76
Study 7805428 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 76
Study 3383985 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pyridoxal 5‐phosphate glutamate (MPPG) 3 x 50 mg for 12 weeks
Number of subjects: 30
Study 3383985 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 30
Study 12057715 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 11
Study 12057715 — intervention group
Group type: COMPARATOR
Intervention: Oral micronized estradiol
Number of subjects: 11
Study 12057715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Transdermal and Oral)
Number of subjects: 11
Study 29871891 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist BI
Number of subjects: 836
Study 29871891 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer BI
Number of subjects: 836
Study 29871891 — intervention group
Group type: COMPARATOR
Intervention: Post-ED BIs
Number of subjects: 836
Study 26840915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh blood transfusions (mean age 4.0 days)
Number of subjects: 20
Study 26840915 — intervention group
Group type: COMPARATOR
Intervention: Standard-issue blood transfusions (mean age 23.2 days)
Number of subjects: 20
Study 25099545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal protein infusion (hydrolyzed whey) 30 kcal
Number of subjects: 20
Study 25099545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal protein infusion (hydrolyzed whey) 90 kcal
Number of subjects: 20
Study 25099545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal protein infusion (hydrolyzed whey) 180 kcal
Number of subjects: 20
Study 25099545 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion, 0 kcal)
Number of subjects: 20
Study 22267334 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunosuppressive (IS) treatment
Number of subjects: 17
Study 22267334 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (Control)
Number of subjects: 17
Study 20384751 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bimatoprost 0.03% applied to the upper lid margin once daily for 12 weeks
Number of subjects: 28
Study 18520801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m on day 1 and Vinorelbine (VNR) 20 mg/m on days 1 and 8 every 4 weeks with concurrent thoracic radiotherapy (TRT) of 60 Gy in 30 fractions.
Number of subjects: 73
Study 16297773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 97
Study 16297773 — intervention group
Group type: COMPARATOR
Intervention: Control (no pravastatin)
Number of subjects: 97
Study 12028321 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan (oral administration)
Number of subjects: 0
Study 10496576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Number of subjects: 66
Study 10496576 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day hyperbaric oxygen treatment (100% oxygen for 1 hour per day at 2.0 atm)
Number of subjects: 66
Study 10496576 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (21% oxygen for 1 hour per day at 1.2 atm)
Number of subjects: 66
Study 8739162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (Corsodyl)
Number of subjects: 19
Study 8739162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine (Eludril)
Number of subjects: 19
Study 1768031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 50
Study 1768031 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 50
Study 7066163 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 27
Study 7066163 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 27
Study 7066163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study 31985248 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis-guided modular intervention (FAMI)
Number of subjects: 0
Study 31985248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (manualized intervention)
Number of subjects: 0
Study 31985248 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (manualized intervention)
Number of subjects: 0
Study 31985248 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study 30610210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection
Number of subjects: 30
Study 30610210 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 30
Study 30235726 — intervention group
Group type: EXPERIMENTAL
Intervention: Yikou-Sizi powder hot compress
Number of subjects: 0
Study 30235726 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27496126 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive training for 30 min over 35 sessions
Number of subjects: 60
Study 27496126 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 23408278 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 667
Study 23408278 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY)
Number of subjects: 667
Study 23408278 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 667
Study 22295883 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy initiated within 72 hours of hospitalization
Number of subjects: 8052
Study 22295883 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 8052
Study 20815975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM
Number of subjects: 45
Study 20815975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18160008 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r 800/200 mg QD
Number of subjects: 190
Study 18160008 — intervention group
Group type: COMPARATOR
Intervention: LPV/r 400/100 mg BID
Number of subjects: 190
Study 16317266 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (50-100 mg/d) with concurrent gemcitabine (75 mg/m2) and paclitaxel (40 mg/m) for 6 weeks, followed by maintenance erlotinib (150 mg/d) until disease progression.
Number of subjects: 17
Study 16317266 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (50 mg/d) with chemoradiation.
Number of subjects: 17
Study 16317266 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib (150 mg/d).
Number of subjects: 17
Study 16317266 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib dosages > or =75 mg/d with chemoradiation.
Number of subjects: 17
Study 12423841 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen plus micronized progesterone cyclical
Number of subjects: 875
Study 12423841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 12423841 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen
Number of subjects: 875
Study 12423841 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate continuous
Number of subjects: 875
Study 12423841 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate cyclical
Number of subjects: 875
Study 9598705 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate drinking among men
Number of subjects: 5887
Study 9598705 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pattern of drinking eight or more drinks per occasion, but less than once a month among men
Number of subjects: 5887
Study 9598705 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5887
Study 7694913 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 70
Study 7694913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2702966 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (maximum tolerated dose: 10.3 +/- 2.3 mg)
Number of subjects: 5
Study 792851 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG)
Number of subjects: 100
Study 792851 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 31289092 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Number of subjects: 0
Study 31289092 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 L split‐dose polyethylene glycol electrolyte solution (PEG‐ELS) preceded by 15 mg of bisacodyl and a low-fibre diet
Number of subjects: 0
Study 31289092 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L split‐dose PEG‐ELS
Number of subjects: 0
Study 31289092 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 L split‐dose PEG‐ELS
Number of subjects: 0
Study 28408544 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 36
Study 28408544 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 36
Study 25937255 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu decoction (SFD)
Number of subjects: 40
Study 23678857 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI followed by LA linear and CFAE ablation
Number of subjects: 210
Study 23678857 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI followed by LA linear, CFAE, and CTI ablations
Number of subjects: 210
Study 23678857 — intervention group
Group type: COMPARATOR
Intervention: PVI and CFAE ablation
Number of subjects: 210
Study 23678857 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after final ablation procedure
Number of subjects: 210
Study 21736777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI meals
Number of subjects: 74
Study 21736777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GL meals
Number of subjects: 74
Study 21736777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI meals
Number of subjects: 74
Study 20014258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064 nm Nd:YAG laser
Number of subjects: 20
Study 20014258 — intervention group
Group type: COMPARATOR
Intervention: 1,320 nm laser
Number of subjects: 20
Study 20014258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064/1,320 nm multiplex laser system
Number of subjects: 20
Study 20014258 — intervention group
Group type: COMPARATOR
Intervention: Tumescent liposculpture
Number of subjects: 20
Study 16567381 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum high-carbohydrate diet (18% fat, 19% protein, 63% carbohydrate)
Number of subjects: 22
Study 16567381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum high-carbohydrate diet plus aerobic exercise training (4 d/wk, 45 min/d, 80% VO(2peak)) for 12 weeks
Number of subjects: 22
Study 16567381 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum high-carbohydrate diet
Number of subjects: 22
Study 16567381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum high-carbohydrate diet plus aerobic exercise training
Number of subjects: 22
Study 12946073 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA injection using the Wand with 1.8 mL of 2% lidocaine solution with 1/80,000 epinephrine
Number of subjects: 20
Study 12946073 — intervention group
Group type: COMPARATOR
Intervention: Control side (no AMSA injection)
Number of subjects: 20
Study 10769922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 10769922 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aerobic exercise
Number of subjects: 0
Study 10769922 — intervention group
Group type: COMPARATOR
Intervention: Lecture group
Number of subjects: 0
Study 9160032 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft (group 1)
Number of subjects: 50
Study 9160032 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mitomycin 0.2 mg/ml four times a day x 7 days (group 2)
Number of subjects: 50
Study 9160032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin 0.4 mg/ml x 3 minutes (group 3)
Number of subjects: 50
Study 8430051 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) MPH
Number of subjects: 11
Study 8430051 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Release (SR) MPH
Number of subjects: 11
Study 8430051 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Release chewed (CH) MPH
Number of subjects: 11
Study 8430051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) MPH
Number of subjects: 11
Study 3027604 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine (3.5-7 micrograms/kg/min)
Number of subjects: 0
Study 3027604 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine with thymoxamine (strong alpha-1-adrenergic antagonist)
Number of subjects: 0
Study 3027604 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (1-12 micrograms/min)
Number of subjects: 0